Pablo Legorreta, Royalty Pharma CEO (David Paul Morris/Bloomberg via Getty Images)

Roy­al­ty Phar­ma pays Fer­ring $300M for 5% roy­al­ty on sales of can­cer gene ther­a­py Ad­sti­ladrin

Fer­ring Phar­ma­ceu­ti­cals is pulling in $300 mil­lion and a po­ten­tial $200 mil­lion mile­stone from Roy­al­ty Phar­ma in ex­change for a 5.1% per­cent­age roy­al­ty on net sales of its gene ther­a­py Ad­sti­ladrin, just as it gears up to roll out the treat­ment com­mer­cial­ly.

The $200 mil­lion mile­stone pay­ment de­pends on hit­ting man­u­fac­tur­ing goals in 2025, while the roy­al­ty pay­ments are ex­pect­ed to end in the ear­ly- to mid-2030s. Ac­cord­ing to Fer­ring, the mon­ey from Roy­al­ty Phar­ma will be used to scale up man­u­fac­tur­ing, com­mer­cial­iza­tion and clin­i­cal de­vel­op­ment for the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.